当前位置:首页 - 行情中心 - 药康生物(688046) - 财务分析 - 利润表

药康生物

(688046)

  

流通市值:69.91亿  总市值:69.91亿
流通股本:4.10亿   总股本:4.10亿

利润表

报告期2025-09-302025-06-302025-03-312024-12-31
公司类型通用通用通用通用
一、营业总收入575,576,818.48374,808,989.09170,855,596.98686,837,009.6
  营业收入575,576,818.48374,808,989.09170,855,596.98686,837,009.6
二、营业总成本446,747,545.25287,113,871.94135,710,404.13580,186,527.9
  营业成本207,114,573.64133,900,946.5963,123,361.52261,052,207.72
  税金及附加2,793,764.331,639,447.13965,377.163,899,209.64
  销售费用80,302,657.5852,544,519.6124,733,025.19107,148,190.94
  管理费用97,781,921.8763,520,904.630,914,953.95132,536,070.83
  研发费用61,991,519.5139,375,707.4718,257,390.787,133,668.26
  财务费用-3,236,891.68-3,867,653.46-2,283,704.39-11,582,819.49
  其中:利息费用4,589,636.572,856,768.621,077,444.954,300,850.78
  其中:利息收入7,248,137.34,885,223.442,229,092.4814,388,671.43
三、其他经营收益
  加:公允价值变动收益2,139,933.56372,000.141,156,726.132,341,561.65
  加:投资收益4,253,017.631,351,054.93289,597.868,003,815.54
  资产处置收益-35,525.54-25,422.09-56,116.9912,516.02
  资产减值损失(新)-13,112,374.01-8,308,552.96-5,887,176.39-21,644,970.29
  信用减值损失(新)-12,298,710.83-8,906,176.93-3,174,098.09-3,276,607.77
  其他收益10,514,550.345,347,148.493,199,528.5827,281,008.72
四、营业利润120,290,164.3877,525,168.7330,673,653.95119,367,805.57
  加:营业外收入4,054.070.440.0114,012.15
  减:营业外支出133,412.6682,948.48-166,819.78
五、利润总额120,160,805.7977,442,220.6930,673,653.96119,214,997.94
  减:所得税费用10,260,731.196,536,743.55693,393.569,395,178.64
六、净利润109,900,074.670,905,477.1429,980,260.4109,819,819.3
(一)按经营持续性分类
  持续经营净利润109,900,074.670,905,477.1429,980,260.4109,819,819.3
(二)按所有权归属分类
  归属于母公司股东的净利润109,900,074.670,905,477.1429,980,260.4109,819,819.3
  扣除非经常损益后的净利润92,785,070.3262,925,408.2925,108,916.5275,743,097.97
七、每股收益
  (一)基本每股收益0.270.170.070.27
  (二)稀释每股收益0.270.170.070.27
八、其他综合收益-471,982.53-555,105.94-98,315.247,553,752.88
  归属于母公司股东的其他综合收益-471,982.53-555,105.94-98,315.247,553,752.88
九、综合收益总额109,428,092.0670,350,371.229,881,945.16117,373,572.18
  归属于母公司股东的综合收益总额109,428,092.0670,350,371.229,881,945.16117,373,572.18
公告日期2025-10-232025-08-232025-04-262025-04-26
审计意见(境内)标准无保留意见
TOP↑